{
  "docId": "019dd923-622c-750b-8b9a-101b5bfde4b8",
  "docSlug": "a70fecd99534",
  "documentTitle": "Berkeley Lights (BLI)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-09-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 99,
  "pageCount": 158,
  "prevPage": 98,
  "nextPage": 100,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses direct quotes from an expert consultation to highlight product deficiencies.",
  "elementsJson": [
    "headline_text",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-101b5bfde4b8/99",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-101b5bfde4b8#slide-99",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Machine's inability to screen more complex antibodies is a major limitation",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-2042-70a9-a1ab-d78feab02376",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "HARBOUR BIOMED (cont'd): Machine can't really screen for complex antibodies, which is where antibody discovery is now gravitating; limits its usability; BLI technology is built around older, simpler antibodies; company seems to have little know-how and couldn't even answer customer questions, who were left to try and figure it out on their own.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7990593f-d3ed-446d-a4ab-a363ecd7dc5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "quote",
      "text": "Machine isn't sensitive enough to screen for more complex antibodies, which is where the field is moving to \"When you start thinking about some of the more complex antibodies that we were looking at like bispecifics and others, those became a little bit difficult to screen in terms of the sensitivity and the specificity of the system. So, that's where most of the field is moving. Single monoclonal antibodies are fine, but as soon as you start going toward the more complex structures, that becomes an issue.\"",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e9c5cea-cb4d-4da8-926d-ef0aa404e6c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.9,
        "x": 0.05,
        "y": 0.72
      },
      "kind": "quote",
      "text": "BLI's technology is built around older, simpler antibodies; company appears to have little expertise and ability to support screening for complex antibodies; unable to support the machine. \"They tried to troubleshoot... their focus was always on the simpler forms of the antibodies... And you wouldn't get anything beyond the typical traditional answer, which means you have to go out there and try it out for yourself, rather than them being helpful...\"",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb148bd8-a33e-4eba-be08-6eab3fc88e41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "quote",
      "text": "Machine's inability to screen more complex antibodies is a major limitation Q: \"What percentage in the field today is moving toward those kinds of antibodies, these more complex ones?\" A: \"A significant amount because a single target is getting more and more complicated... and that's where the field is going, and that's where some of the complex work takes place that wasn't able to be done with the Berkeley Lights system.\"",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1b2777e-8b48-40d8-830a-3d8cb3734c40",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"When you start thinking about some of the more complex antibodies that we were looking at like bispecifics and others, those became a little bit difficult to screen in terms of the sensitivity and the specificity of the system. So, that's where most of the field is moving. Single monoclonal antibodies are fine, but as soon as you start going toward the more complex structures, that becomes an issue.\" — Harbour Biomed ex-executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-2042-70a9-a1ab-d81b856d1c9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01ff630d-d5f0-45d7-b75a-2f9c5df6b0af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "2K) Harbour Biomed ex-executive",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "000479bd-ac0c-40ae-bdd2-2e99e644d469",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 150,
      "from": 42,
      "beatId": "172d6e2f-be3f-4802-92e5-e7e412ccdabe",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Testimonials from Customers and Former Employees",
      "beatSlug": null,
      "evidence": "The document presents testimonials from customers and former employees, providing first-hand accounts of the challenges and limitations of Berkeley Lights' product.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}